| Literature DB >> 33264613 |
Lorella Marselli1, Anthony Piron2, Mara Suleiman3, Maikel L Colli2, Xiaoyan Yi2, Amna Khamis4, Gaelle R Carrat5, Guy A Rutter6, Marco Bugliani3, Laura Giusti7, Maurizio Ronci8, Mark Ibberson9, Jean-Valery Turatsinze2, Ugo Boggi10, Paolo De Simone11, Vincenzo De Tata12, Miguel Lopes2, Daniela Nasteska2, Carmela De Luca3, Marta Tesi3, Emanuele Bosi3, Pratibha Singh2, Daniela Campani13, Anke M Schulte14, Michele Solimena15, Peter Hecht14, Brian Rady16, Ivona Bakaj16, Alessandro Pocai16, Lisa Norquay16, Bernard Thorens17, Mickaël Canouil4, Philippe Froguel18, Decio L Eizirik19, Miriam Cnop20, Piero Marchetti21.
Abstract
Pancreatic β cell failure is key to type 2 diabetes (T2D) onset and progression. Here, we assess whether human β cell dysfunction induced by metabolic stress is reversible, evaluate the molecular pathways underlying persistent or transient damage, and explore the relationships with T2D islet traits. Twenty-six islet preparations are exposed to several lipotoxic/glucotoxic conditions, some of which impair insulin release, depending on stressor type, concentration, and combination. The reversal of dysfunction occurs after washout for some, although not all, of the lipoglucotoxic insults. Islet transcriptomes assessed by RNA sequencing and expression quantitative trait loci (eQTL) analysis identify specific pathways underlying β cell failure and recovery. Comparison of a large number of human T2D islet transcriptomes with those of persistent or reversible β cell lipoglucotoxicity show shared gene expression signatures. The identification of mechanisms associated with human β cell dysfunction and recovery and their overlap with T2D islet traits provide insights into T2D pathogenesis, fostering the development of improved β cell-targeted therapeutic strategies.Entities:
Keywords: beta cells; damage; eQTL; endoplasmic reticulum stress; glucolipotoxicity; human pancreatic islets; lipoglucotoxicity; recovery; transcriptome; type 2 diabetes
Mesh:
Year: 2020 PMID: 33264613 DOI: 10.1016/j.celrep.2020.108466
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423